HOME > 상세정보

상세정보

Small molecules in oncology [electronic resource] / 2nd ed

Small molecules in oncology [electronic resource] / 2nd ed

자료유형
E-Book(소장)
개인저자
Martens, Uwe M.
서명 / 저자사항
Small molecules in oncology [electronic resource] / Uwe M. Martens (ed.).
판사항
2nd ed.
발행사항
Berlin;   Heidelberg :   Springer Berlin Heidelberg :   Imprint: Springer,   2014.  
형태사항
1 online resource (xvi, 417 p.) : ill. (some col.).
총서사항
Recent results in cancer research,0080-0015 ; 201
ISBN
9783642544903
요약
Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
일반주기
Title from e-Book title page.  
내용주기
Imatinib Mesylate -- Erlotinib -- Axitinib (AG-013736) -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Decitabine -- Azacytidine/Azacitidine -- Bortezomib -- Temsirolimus -- Danusertib -- Vismodegib -- Everolimus -- Vemurafenib -- Vandetanib -- Trametinib -- Dabrafenib -- Ponatinib -- Regorafenib -- Cabozantinib -- Revlimid -- Ibrutinib -- Qizartinib -- Ruxolitinib -- Carfilzomib -- Afitinib.
서지주기
Includes bibliographical references.
이용가능한 다른형태자료
Issued also as a book.  
일반주제명
Cancer --Molecular aspects. Antineoplastic agents. Cancer --Treatment. Neoplasms --drug therapy. Antineoplastic Agents --therapeutic use. Azacitidine --therapeutic use. Protein Kinase Inhibitors --therapeutic use.
바로가기
URL
000 00000nam u2200205 a 4500
001 000046049850
005 20201015131542
006 m d
007 cr
008 201005s2014 gw a ob 000 0 eng d
020 ▼a 9783642544903
040 ▼a 211009 ▼c 211009 ▼d 211009
050 4 ▼a RC254-282
082 0 4 ▼a 616.994061 ▼2 22
084 ▼a 616.994061 ▼2 DDCK
090 ▼a 616.994061
245 0 0 ▼a Small molecules in oncology ▼h [electronic resource] / ▼c Uwe M. Martens (ed.).
250 ▼a 2nd ed.
260 ▼a Berlin; ▼a Heidelberg : ▼b Springer Berlin Heidelberg : ▼b Imprint: Springer, ▼c 2014.
300 ▼a 1 online resource (xvi, 417 p.) : ▼b ill. (some col.).
490 1 ▼a Recent results in cancer research, ▼x 0080-0015 ; ▼v 201
500 ▼a Title from e-Book title page.
504 ▼a Includes bibliographical references.
505 0 ▼a Imatinib Mesylate -- Erlotinib -- Axitinib (AG-013736) -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Decitabine -- Azacytidine/Azacitidine -- Bortezomib -- Temsirolimus -- Danusertib -- Vismodegib -- Everolimus -- Vemurafenib -- Vandetanib -- Trametinib -- Dabrafenib -- Ponatinib -- Regorafenib -- Cabozantinib -- Revlimid -- Ibrutinib -- Qizartinib -- Ruxolitinib -- Carfilzomib -- Afitinib.
520 ▼a Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
530 ▼a Issued also as a book.
538 ▼a Mode of access: World Wide Web.
650 0 ▼a Cancer ▼x Molecular aspects.
650 0 ▼a Antineoplastic agents.
650 0 ▼a Cancer ▼x Treatment.
650 1 2 ▼a Neoplasms ▼x drug therapy.
650 2 2 ▼a Antineoplastic Agents ▼x therapeutic use.
650 2 2 ▼a Azacitidine ▼x therapeutic use.
650 2 2 ▼a Protein Kinase Inhibitors ▼x therapeutic use.
700 1 ▼a Martens, Uwe M.
830 0 ▼a Recent results in cancer research ; ▼v 201.
856 4 0 ▼u https://oca.korea.ac.kr/link.n2s?url=http://dx.doi.org/10.1007/978-3-642-54490-3
945 ▼a KLPA
991 ▼a E-Book(소장)

소장정보

No. 소장처 청구기호 등록번호 도서상태 반납예정일 예약 서비스
No. 1 소장처 중앙도서관/e-Book 컬렉션/ 청구기호 CR 616.994061 등록번호 E14034710 도서상태 정리중 반납예정일 예약 서비스 M

관련분야 신착자료

WHO Classification of Tumours Editorial Board (2021)
대한가정의학회. 비만대사증후군연구회 (2021)
Santiago-Cardona, Pedro G (2021)
Hargadon, Kristian M (2021)
Stein, Ulrike S (2021)